A Brazilian Inter-Hospital Candidemia Outbreak Caused by Fluconazole-Resistant Candida parapsilosis in the COVID-19 Era

Carregando...
Imagem de Miniatura
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Citação
JOURNAL OF FUNGI, v.8, n.2, article ID 100, 8p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Horizontal transmission of fluconazole-resistant Candida parapsilosis (FRCP) through healthcare workers' hands has contributed to the occurrence of candidemia outbreaks worldwide. Since the first COVID-19 case in Brazil was detected in early 2020, hospitals have reinforced hand hygiene and disinfection practices to minimize SARS-CoV-2 contamination. However, a Brazilian cardiology center, which shares ICU patients with a cancer center under a FRCP outbreak since 2019, reported an increased FRCP candidemia incidence in May 2020. Therefore, the purpose of this study was to investigate an inter-hospital candidemia outbreak caused by FRCP isolates during the first year of the COVID-19 pandemic in Brazil. C. parapsilosis bloodstream isolates obtained from the cancer (n = 35) and cardiology (n = 30) centers in 2020 were submitted to microsatellite genotyping and fluconazole susceptibility testing. The ERG11 gene of all isolates from the cardiology center was sequenced and compared to the corresponding sequences of the FRCP genotype responsible for the cancer center outbreak in 2019. Unprecedentedly, most of the FRCP isolates from the cardiology center presented the same genetic profile and Erg11-Y132F mutation detected in the strain that has been causing the persistent outbreak in the cancer center, highlighting the uninterrupted horizontal transmission of clonal isolates in our hospitals during the COVID-19 pandemic.
Palavras-chave
inter-hospital transmission, clonal outbreak, candidemia, Candida parapsilosis, microsatellite typing, antifungal agents, azole-resistant, drug resistance mechanisms, ERG11 mutations, COVID-19 pandemic
Referências
  1. Abdolrasouli A, 2017, MYCOSES, V60, P758, DOI 10.1111/myc.12699
  2. Arastehfar A, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.676177
  3. Arastehfar A, 2020, J FUNGI, V6, DOI 10.3390/jof6040211
  4. Bassetti M, 2019, SEMIN RESP CRIT CARE, V40, P524, DOI 10.1055/s-0039-1693704
  5. Castanheira M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2019.09.003
  6. Choi YJ, 2018, EMERG INFECT DIS, V24, P1768, DOI 10.3201/eid2409.180625
  7. CLSI, 2018, M44 CLSI, V3rd ed.
  8. Cobb N, 2021, AM J TROP MED HYG, V104, P25, DOI 10.4269/ajtmh.20-1009
  9. Conti A, 2018, NEPHROLOGY, V23, P863, DOI 10.1111/nep.13101
  10. Corzo-Leon DE, 2021, MED MYCOL, V59, P664, DOI 10.1093/mmy/myaa098
  11. da Silva EM, 2021, J MYCOL MED, V31, DOI 10.1016/j.mycmed.2020.101110
  12. de Almeida JN, 2021, J FUNGI, V7, DOI 10.3390/jof7030220
  13. Epelbaum O, 2017, CLIN CHEST MED, V38, P493, DOI 10.1016/j.ccm.2017.04.010
  14. Ezeokoli OT, 2021, J FUNGI, V7, DOI 10.3390/jof7070545
  15. Fekkar A, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.02036-20
  16. Fu LW, 2020, J INFECT PUBLIC HEAL, V13, P730, DOI 10.1016/j.jiph.2020.01.008
  17. Inglis R, 2021, AM J TROP MED HYG, V104, P12, DOI 10.4269/ajtmh.20-1128
  18. Kaur H, 2017, J FUNGI, V3, DOI 10.3390/jof3030041
  19. Kim JH, 2021, J FUNGI, V7, DOI 10.3390/jof7040275
  20. Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
  21. Magobo RE, 2020, MYCOSES, V63, P471, DOI 10.1111/myc.13070
  22. Marinho PRD, 2021, CYTOKINE GROWTH F R, V58, P51, DOI 10.1016/j.cytogfr.2020.10.010
  23. McCarty TP, 2021, INFECT DIS CLIN N AM, V35, P389, DOI 10.1016/j.idc.2021.03.007
  24. Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
  25. Pulcrano G, 2012, EUR J CLIN MICROBIOL, V31, P2919, DOI 10.1007/s10096-012-1642-6
  26. Sakita KM, 2017, MICROB PATHOGENESIS, V113, P225, DOI 10.1016/j.micpath.2017.10.044
  27. SALZMAN MB, 1993, J CLIN MICROBIOL, V31, P475, DOI 10.1128/JCM.31.3.475-479.1993
  28. Shuping L, 2021, PEDIATR INFECT DIS J, V40, P730, DOI 10.1097/INF.0000000000003151
  29. Soulountsi V, 2021, INFECTION, V49, P1107, DOI 10.1007/s15010-021-01640-7
  30. Souza ACR, 2015, ANTIMICROB AGENTS CH, V59, P6581, DOI 10.1128/AAC.01177-15
  31. Tauffer J, 2021, AM J INFECT CONTROL, V49, P1464, DOI 10.1016/j.ajic.2021.09.015
  32. Thomaz DY, 2021, J FUNGI, V7, DOI 10.3390/jof7040259
  33. Thomaz DY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02997
  34. Toth R, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00111-18
  35. Tsay SV, 2020, CLIN INFECT DIS, V71, pE449, DOI 10.1093/cid/ciaa193
  36. Welsh RM, 2017, J CLIN MICROBIOL, V55, P2996, DOI [10.1128/JCM.00921-17, 10.1128/jcm.00921-17]
  37. Zoppo M, 2021, J FUNGI, V7, DOI 10.3390/jof7060459